Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-CD19 Chimeric Antigen Receptor T cell - Guangdong Zhaotai Cell Bio-tech

X
Drug Profile

Anti-CD19 Chimeric Antigen Receptor T cell - Guangdong Zhaotai Cell Bio-tech

Alternative Names: CAR19T2 T Cell - Guangdong Zhaotai Cell Bio-tech; CD19 CAR T-cell - Guangdong Zhaotai Cell Bio-tech

Latest Information Update: 27 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Unknown
  • Developer Guangdong Zhaotai InVivo Biomedicine
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Haematological malignancies

Most Recent Events

  • 18 Mar 2024 Guangdong Zhaotai Cell Bio-tech withdraws a phase I/II trial in B-cell lymphoma in China (IV) prior to enrollment as company failed to provide the corresponding CAR-T services(NCT05613348)
  • 16 Nov 2022 Preclinical trials in Haematological malignancies in China (IV) (NCT05613348)
  • 16 Nov 2022 Guangdong Zhaotai Cell Bio-tech plans to initiate a phase I/II trial to evaluate CAR19T2 T Cell in children with B-cell Leukemia/Lymphoma (NCT05613348)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top